HomeCompareOCUP vs KMB

OCUP vs KMB: Dividend Comparison 2026

OCUP yields 170.94% · KMB yields 5.25%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 OCUP wins by $49.52M in total portfolio value
10 years
OCUP
OCUP
● Live price
170.94%
Share price
$1.17
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.57M
Annual income
$23,046,519.63
Full OCUP calculator →
KMB
KMB
● Live price
5.25%
Share price
$96.47
Annual div
$5.06
5Y div CAGR
17%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$45.9K
Annual income
$5,211.33
Full KMB calculator →

Portfolio growth — OCUP vs KMB

📍 OCUP pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodOCUPKMB
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, OCUP + KMB cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
OCUP pays
KMB pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

OCUP
Annual income on $10K today (after 15% tax)
$14,529.91/yr
After 10yr DRIP, annual income (after tax)
$19,589,541.69/yr
KMB
Annual income on $10K today (after 15% tax)
$445.84/yr
After 10yr DRIP, annual income (after tax)
$4,429.63/yr
At 15% tax rate, OCUP beats the other by $19,585,112.06/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of OCUP + KMB for your $10,000?

OCUP: 50%KMB: 50%
100% KMB50/50100% OCUP
Portfolio after 10yr
$24.81M
Annual income
$11,525,865.47/yr
Blended yield
46.46%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on KMB right now

OCUP
No analyst data
Altman Z
-6.1
Piotroski
3/9
KMB
Analyst Ratings
9
Buy
19
Hold
3
Sell
Consensus: Hold
Price Target
$123.00
+27.5% upside vs current
Range: $102.00 — $162.00
Altman Z
3.4
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

OCUP buys
0
KMB buys
0
No recent congressional trades found for OCUP or KMB in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricOCUPKMB
Forward yield170.94%5.25%
Annual dividend / share$2.00$5.06
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%17%
Portfolio after 10y$49.57M$45.9K
Annual income after 10y$23,046,519.63$5,211.33
Total dividends collected$46.28M$21.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: OCUP vs KMB ($10,000, DRIP)

YearOCUP PortfolioOCUP Income/yrKMB PortfolioKMB Income/yrGap
1← crossover$27,794$17,094.02$11,314$613.68+$16.5KOCUP
2$74,143$44,402.93$12,865$759.19+$61.3KOCUP
3$190,032$110,699.08$14,709$943.96+$175.3KOCUP
4$468,500$265,166.46$16,919$1,180.17+$451.6KOCUP
5$1,112,264$610,968.56$19,588$1,484.33+$1.09MOCUP
6$2,545,727$1,355,604.69$22,838$1,879.06+$2.52MOCUP
7$5,623,629$2,899,701.52$26,832$2,395.60+$5.60MOCUP
8$12,003,803$5,986,519.26$31,788$3,077.63+$11.97MOCUP
9$24,786,500$11,942,431.58$38,000$3,986.82+$24.75MOCUP
10$49,568,075$23,046,519.63$45,872$5,211.33+$49.52MOCUP

OCUP vs KMB: Complete Analysis 2026

OCUPStock

Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate, which is in Phase III clinical trial for dim light or night vision disturbances; and Phase 2b clinical trial for pharmacologically induced mydriasis, as well as that has completed Phase 2 VEGA-1 trial for presbyopia. The company also develops APX3330, a twice-a-day oral tablet to target pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy and diabetic macular edema; and APX2009 and APX2014 second generation preclinical product candidates and analogs of APX3330. Ocuphire Pharma, Inc. is headquartered in Farmington Hills, Michigan.

Full OCUP Calculator →

KMBConsumer Staples

Kimberly-Clark Corporation, together with its subsidiaries, manufactures and markets personal care and consumer tissue products worldwide. It operates through three segments: Personal Care, Consumer Tissue, and K-C Professional. The Personal Care segment offers disposable diapers, swimpants, training and youth pants, baby wipes, feminine and incontinence care products, and other related products under the Huggies, Pull-Ups, Little Swimmers, GoodNites, DryNites, Sweety, Kotex, U by Kotex, Intimus, Depend, Plenitud, Softex, Poise, and other brand names. The Consumer Tissue segment provides facial and bathroom tissues, paper towels, napkins, and related products under the Kleenex, Scott, Cottonelle, Viva, Andrex, Scottex, Neve, and other brand names. The K-C Professional segment offers wipers, tissues, towels, apparel, soaps, and sanitizers under the Kleenex, Scott, WypAll, Kimtech, and KleenGuard brands. The company sells household use products directly to supermarkets, mass merchandisers, drugstores, warehouse clubs, variety and department stores, and other retail outlets, as well as through other distributors and e-commerce; and away-from-home use products directly to manufacturing, lodging, office building, food service, and public facilities, as well as through distributors and e-commerce. Kimberly-Clark Corporation was founded in 1872 and is headquartered in Dallas, Texas.

Full KMB Calculator →
📬

Get this OCUP vs KMB comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

OCUP vs SCHDOCUP vs JEPIOCUP vs OOCUP vs KOOCUP vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.